# A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted Conditions

> **NCT00673088** · NA · COMPLETED · sponsor: **Roxane Laboratories** · enrollment: 30 (actual)

## Conditions studied

- Parkinson's Disease
- Restless Leg Syndrome

## Interventions

- **DRUG:** Ropinirole Hydrochloride

## Key facts

- **NCT ID:** NCT00673088
- **Lead sponsor:** Roxane Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2004-02
- **Final completion:** 2004-02
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2018-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00673088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00673088, "A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted Conditions". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00673088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*